Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proactive vs reactive therapeutic drug monitoring of adalimumab in Crohn's disease
ChiCTR2000036845Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in Crohn's disease (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Clinical remission at 52 weeks. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2000036845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036845.